FIELD: medicine.
SUBSTANCE: diabetes mellitus is simulated in rats by intraperitoneal introduction of alloxan 15.0 mg/100 g of body weight. Murine VEGF 164 is introduced into a vitreous body from an intravitreal approach 6.5 weeks later on the 1st, 3rd and 7th day in a dose of 1 mcg with a total dose of 3 mcg.
EFFECT: method provides macular neovascularisation specific for diabetes mellitus that enables the further study of the therapeutic effectiveness and applicability in the given disease.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SIMULATING DIABETIC MACULAR OEDEMA | 2012 |
|
RU2498415C1 |
| USE OF CABERGOLINE IN TREATING PATHOLOGICAL CONDITIONS CAUSED BY HIGH LEVELS OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR | 2016 |
|
RU2698728C1 |
| METHOD FOR SIMULATING ANTERIOR SEGMENT NEOVASCULARISATION IN RATS | 2012 |
|
RU2488891C1 |
| METHOD FOR STIMULATING NEOVASCULARISATION OF RETINA AND OPTIC NERVE IN RABBITS | 2009 |
|
RU2408083C1 |
| METHOD OF TREATING OPHTHALMIC ANGIOGENESIS, RETINAL OEDEMA, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2445096C2 |
| METHODS OF TREATING OCULAR ANGIOGENESIS, RETINAL HYPOSTASIS, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2396956C2 |
| COMBINED METHOD FOR TREATING CHOROIDAL NEOVASCULATION OF ALL TYPES | 2021 |
|
RU2770745C1 |
| METHOD OF COMBINED TREATMENT OF SEVERE FORMS OF SECONDARY NEOVASCULAR GLAUCOMA | 2019 |
|
RU2708059C1 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
